Ranbaxy Begins Shipping Generic Lipitor From Indian Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ranbaxy Begins Shipping Generic Lipitor From Indian Facility


ePT--the Electronic Newsletter of Pharmaceutical Technology

Ranbaxy Laboratories has announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer’s Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.

Ranbaxy had received approval from FDA in November 2011, to produce atorvastatin at its Ohm Laboratory site in the US, but its Paonta Sahib, Batamandi, and Dewas, India facilities have been on FDA import alert since 2008. According to the company’s press release, Ranbaxy’s Mohali facility was granted approval from FDA in October 2011 to manufacture and market atorvastatin 10-, 20-, 40-, and 80-mg tablets. Ranbaxy expects the Mohali facility to manufacture oral solid products for export to US, EU, and other countries based on filings and after receiving the necessary approvals.

Arun Sawhney, CEO and managing director of Ranbaxy, said in the release, “The resumption of supplies from India into the US market, is a significant milestone for Ranbaxy. This is a testimony to our commitment to provide quality affordable medicines to the US healthcare system. Going forward, our Mohali facility will cater to the US and other geographies, improving access to medicines, in these regions.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here